Survodutide is an experimental medicine that copies two of the body's own hormones at once: GLP-1 and glucagon. It is given as a once-weekly injection and is being tested in large trials for obesity and for a fatty-liver disease called MASH. It is still investigational — not approved anywhere — but its mid-stage results have drawn serious attention.
In plain terms: it is a two-target cousin of semaglutide, and the second target it picks is glucagon.
(The figure above illustrates the dual-agonist idea. Note the exact pair differs: tirzepatide combines GIP + GLP-1, while survodutide combines glucagon + GLP-1.)
What it is
Survodutide (research code BI 456906, developed by Boehringer Ingelheim and Zealand Pharma) is a single engineered peptide — a short chain of amino acids, the building blocks of proteins. It is designed to act like two hormones your gut and pancreas make naturally3.
The two hormones it mimics are:
- GLP-1 (glucagon-like peptide-1) — a gut hormone that curbs appetite and helps the body release insulin. This is the same target semaglutide uses.
- Glucagon — a pancreas hormone that, among other jobs, raises how much energy the body burns and helps mobilise fat, including fat stored in the liver.
Because it switches on two receptors, survodutide is called a dual agonist. An "agonist" is simply a molecule that activates a receptor, the way a key turns a lock.
The mechanism: two levers, not one
The idea behind survodutide is that appetite and energy-burning are two different levers, and pulling both may do more than pulling either alone.
- The GLP-1 receptor lever lowers appetite and slows how fast the stomach empties, so people feel full sooner.
- The glucagon receptor lever is thought to raise energy expenditure — the calories the body burns at rest — and to drive fat out of the liver3.
In plain terms: the GLP-1 side helps you eat less; the glucagon side is meant to help you burn more. The engineering trick is balancing the two so the glucagon action helps metabolism without unwanted effects on blood sugar.
Pharmacokinetics: why once a week
"Pharmacokinetics" just means what the body does to a drug over time — how long it lasts. Survodutide's reported half-life (the time for half a dose to clear) is roughly 6 days3. It clings tightly to albumin, a protein in blood, which slows its breakdown. That long half-life is what makes a once-weekly injection possible — the same weekly rhythm as semaglutide (~7 days) and tirzepatide (~5 days).
| Property | Survodutide (reported) |
|---|---|
| Receptor targets | GLP-1 + glucagon (dual agonist) |
| Route studied | Subcutaneous (under the skin) |
| Reported half-life | ~6 days |
| Dosing rhythm studied | Once weekly |
| Approval status (2026) | Investigational (phase 3) |
What the trials actually found
Survodutide's phase-2 results are what put it on the map. "Phase 2" means a mid-stage human trial — bigger than a first safety study, smaller than the phase-3 trials that support approval. Note the model in each row.
| Trial | People | Key result | Year |
|---|---|---|---|
| Zimmermann et al. — preclinical3 | Rodent / cell studies | Confirmed balanced GLP-1 + glucagon activity and strong weight-loss effect in animals | 2022 |
| le Roux et al. — phase 2 obesity1 | 386 adults with overweight/obesity | On the top dose, completers lost ~19% of body weight at 46 weeks; ~40% lost 20% or more | 2024 |
| Sanyal et al. — phase 2 MASH2 | 293 adults with MASH + fibrosis | MASH improved without worsening scarring in up to 62% (top dose) vs 14% on placebo | 2024 |
In plain terms: in a mid-stage obesity trial, the average completer on the highest dose lost close to a fifth of their body weight over roughly a year1. And in a separate liver-focused trial, the extra glucagon action appeared to calm fatty-liver disease in most participants without making scarring worse2. MASH stands for metabolic dysfunction-associated steatohepatitis — a fatty-liver disease where fat build-up drives inflammation and scarring.
Keep the honesty in view: these are phase-2 results. Encouraging and human, but mid-stage — the large phase-3 trials that decide approval were still running.
Practical notes and handling
Survodutide has been studied as a subcutaneous (under-the-skin) once-weekly injection, with doses raised slowly over weeks in the trials — a "dose-escalation" schedule used to ease the nausea that GLP-1-class drugs commonly cause early on. This page describes what the trials used; it is educational and does not tell anyone how to use anything.
The most common side effects reported in the trials were gastrointestinal — nausea, vomiting, and diarrhoea — the familiar pattern for this drug class, generally strongest during dose increases.
Honest limitations
This is the key line: survodutide is not an approved medicine. As of 2026 it is in late-stage clinical testing (the phase-3 SYNCHRONIZE program for obesity, plus ongoing MASH studies) and has no regulatory approval for any use. Everything known about it comes from clinical trials, not years of real-world use. The long-term safety of adding glucagon activity — including its effects on heart rate and blood sugar — is exactly what the larger trials are designed to pin down. This page explains what it is and what the trials showed, not how to use it, and takes no position on sourcing.
Latest research
- The 2024 phase-2 obesity trial remains a headline result: ~19% weight loss in completers at 46 weeks on the top dose, with the weight curve still trending down at the end — hinting more loss might have followed1.
- The 2024 phase-2 MASH trial extended the story to fatty liver: up to 62% of the top-dose group saw their MASH improve without worsening fibrosis, versus 14% on placebo2.
- Phase-3 trials are ongoing. The SYNCHRONIZE obesity program and a phase-3 MASH program will determine whether these mid-stage numbers hold up and whether survodutide reaches approval. We update this section as results report.
The short version
Survodutide is an investigational GLP-1 / glucagon dual agonist — a once-weekly peptide that lowers appetite through GLP-1 and is thought to raise energy-burning and clear liver fat through glucagon. In phase-2 trials it produced ~19% weight loss and improved fatty-liver disease in most participants, but it is not approved and its phase-3 trials were still running. Educational overview only, not medical advice.